Neurovalens successfully secured 510(k) clearance from the FDA on October 27, 2023 for its Modius Sleep device with relation to treatment of insomnia and/or anxiety. The clearance was supported by ...
BELFAST, Northern Ireland, Feb. 24, 2025 /PRNewswire/ -- Neurovalens, a global leader in noninvasive neurostimulation technology, is making significant strides in addressing chronic insomnia among U.S ...
Neurovalens Ltd raised £6 million (US$8 million) in an investment round for its non-invasive neurostimulation devices, which treat insomnia and manage anxiety. The company will use the funds to expand ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results